drugset
drugset / Trial / NCT00214955

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain

NCT00214955 ↗

Phase 3 Completed 120 enrolled Cephalon
RandomizedFactorialDouble-blindTreatment

Summary

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Neuropathic Pain

Timeline

Start
2005-09
Primary completion
2006-05
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified — —

Indications

neuropathy, painful